We Give Shareholders a Voice

Portola Pharmaceuticals, Inc. Information Request Form

Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Portola Pharmaceuticals, Inc. (“Portola” or the “Company”) (NASDAQ: PTLA) to Alexion Pharmaceuticals, Inc. (“Alexion”) (NASDAQ: ALXN). Under the terms of the merger, a subsidiary of Alexion will commence a tender offer to acquire all of the outstanding shares of Portola‚Äôs common stock at a price of $18 per share in cash.

The Portola merger investigation concerns whether the Board of Portola breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into this transaction and whether Alexion is underpaying for Portola shares, thus unlawfully harming Portola shareholders.

To receive more information, please fill out the form.

Enter Your Details Below

This submission does not create an attorney-client relationship. We will keep you up to date with this investigation, and should this investigation evolve, we will contact you to discuss whether to establish an attorney client relationship at no cost to you.

Review our Privacy Policy